Literature DB >> 12445832

Phosphorylation of Bruton's tyrosine kinase by c-Abl.

Carl Magnus Bäckesjö1, Leonardo Vargas, Giulio Superti-Furga, C I Smith.   

Abstract

Bruton's tyrosine kinase (Btk) is necessary for B-lymphocyte development. Mutation in the gene coding for Btk causes X-linked agammaglobulinemia (XLA) in humans. Similar to Btk, c-Abl is a tyrosine kinase shuttling between the cytoplasm and the nucleus where it is involved in different functions depending on the localization. In this report we describe for the first time that c-Abl and Btk physically interact and that c-Abl can phosphorylate tyrosine 223 in the SH3 domain of Btk. Interestingly, the Btk sequence matched a v-Abl substrate [correction] identified from a randomized peptide library and was also highly related to a number of previously found c-Abl substrates.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445832     DOI: 10.1016/s0006-291x(02)02643-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  c-Abl-deficient mice exhibit reduced numbers of peritoneal B-1 cells and defects in BCR-induced B cell activation.

Authors:  Rachel A Liberatore; Stephen P Goff
Journal:  Int Immunol       Date:  2009-02-19       Impact factor: 4.823

2.  The effects of c-Abl mutation on developing B cell differentiation and survival.

Authors:  Hans Brightbill; Mark S Schlissel
Journal:  Int Immunol       Date:  2009-03-19       Impact factor: 4.823

3.  Regulation of nucleocytoplasmic shuttling of Bruton's tyrosine kinase (Btk) through a novel SH3-dependent interaction with ankyrin repeat domain 54 (ANKRD54).

Authors:  Manuela O Gustafsson; Alamdar Hussain; Dara K Mohammad; Abdalla J Mohamed; Vivian Nguyen; Pavel Metalnikov; Karen Colwill; Tony Pawson; C I Edvard Smith; Beston F Nore
Journal:  Mol Cell Biol       Date:  2012-04-23       Impact factor: 4.272

4.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

5.  Conformation of full-length Bruton tyrosine kinase (Btk) from synchrotron X-ray solution scattering.

Authors:  José A Márquez; C I Edvard Smith; Maxim V Petoukhov; Paola Lo Surdo; Pekka T Mattsson; Marika Knekt; Anna Westlund; Klaus Scheffzek; Matti Saraste; Dmitri I Svergun
Journal:  EMBO J       Date:  2003-09-15       Impact factor: 11.598

6.  A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis.

Authors:  Cheryl Eifert; Xianhui Wang; Leila Kokabee; Antonis Kourtidis; Ritu Jain; Michael J Gerdes; Douglas S Conklin
Journal:  Genes Chromosomes Cancer       Date:  2013-08-03       Impact factor: 5.006

7.  Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors.

Authors:  Haiyang Chen; Peiran Song; Yanyan Diao; Yongjia Hao; Dou Dou; Wanqi Wang; Xiaoyu Fang; Yanling Wang; Zhenjiang Zhao; Jian Ding; Honglin Li; Hua Xie; Yufang Xu
Journal:  Medchemcomm       Date:  2018-03-13       Impact factor: 3.597

8.  Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells.

Authors:  Niklas Feldhahn; Florian Klein; Jana L Mooster; Paul Hadweh; Mieke Sprangers; Maria Wartenberg; Mohamed M Bekhite; Wolf-Karsten Hofmann; Sebastian Herzog; Hassan Jumaa; Janet D Rowley; Markus Müschen
Journal:  J Exp Med       Date:  2005-06-06       Impact factor: 14.307

Review 9.  Ibrutinib and novel BTK inhibitors in clinical development.

Authors:  Akintunde Akinleye; Yamei Chen; Nikhil Mukhi; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-08-19       Impact factor: 17.388

10.  Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function.

Authors:  Daniel Trageser; Ilaria Iacobucci; Rahul Nahar; Cihangir Duy; Gregor von Levetzow; Lars Klemm; Eugene Park; Wolfgang Schuh; Tanja Gruber; Sebastian Herzog; Yong-mi Kim; Wolf-Karsten Hofmann; Aihong Li; Clelia Tiziana Storlazzi; Hans-Martin Jäck; John Groffen; Giovanni Martinelli; Nora Heisterkamp; Hassan Jumaa; Markus Müschen
Journal:  J Exp Med       Date:  2009-07-20       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.